Diabetes Res Clin Pract. 2014 Sep 28. pii: S0168-8227(14)00395-7. doi: 10.1016/j.diabres.2014.08.030. Epub ahead of print
Elkassaby S1, Harrison LC2, Mazzitelli N1, Wentworth JM3, Colman PG4, Spelman T5, Fourlanos S6.
Supplementation with 6,000 IU for 6 months
|Baseline||3 months||6 months|
|Vitamin D||24 ng||60 ng||51 ng|
|fasting plasma glucose||-0.4||0 vs placebo|
|post-prandial blood glucose||-.3 |
|0 vs placebo|
- 60 ng helped, but later 50 ng did not
- Vitamin D drop from month 3 to month 6
Do not recall seeing this in RCT with other diseases
- Perhaps something changed in the gut which reduced the bio-availability
Example: chime spend less time in the gut in months 3-6 ==> less absoption of vitamin D
- Perhaps the trial was run during a single year and the last 3 months were during the winter - when D levels normally drops
- If the vitamin D supplementation had been raised in months 3-6 would the benefits would have been maintained?
Vitamin D insufficiency has been associated with impaired pancreatic beta-cell function. We aimed to determine if high dose oral vitamin D3 (D) improves beta-cell function and glycaemia in type 2 diabetes.
Fifty adults with type 2 diabetes diagnosed less than 12 months, with normal baseline serum 25-OH D (25D), were randomised to 6000IU D (n=26) or placebo (n=24) daily for 6 months. Beta-cell function was measured by glucagon-stimulated serum C-peptide (delta C-peptide DCP, nmol/l). Secondary outcome measures were fasting plasma glucose (FPG), post-prandial blood glucose (PPG), HbA1c and insulin resistance (HOMA-IR).
In the D group, median serum 25D (nmol/l) increased from 59 to 150 (3 months) and 128 (6 months) and median serum 1,25D (pmol/l) from 135 to 200 and 190. After 3 months, change in DCP from baseline in D (+0.04) and placebo (-0.08) was not different (P=0.112).
However, change in FPG (mmol/l) was significantly lower in D (-0.40) compared to placebo (+0.1) (P=0.007), as was the change in PPG in D (-0.30) compared to placebo (+0.8) (P=0.005). Change in HbA1c (%) between D (-0.20) and placebo (-0.10) was not different (P=0.459). At 6 months, changes from baseline in DCP, FPG, PPG and HbA1c were not different between groups.
Oral D3 supplementation in type 2 diabetes was associated with transient improvement in glycaemia, but without a measurable change in beta-cell function this effect is unlikely to be biologically significant. High dose D3 therefore appears to offer little or no therapeutic benefit in type 2 diabetes.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.
- Overview Diabetes and vitamin D contains the following summary
- Diabetes is 5X more frequent far from the equator
- Children getting 2,000 IU of vitamin D are 8X less likely to get Type 1 diabetes
- Obese people get less sun / Vitamin D - and also vitamin D gets lost in fat
- Sedentary people get less sun / Vitamin D
- Worldwide Diabetes increase has been concurrent with vitamin D decrease and air conditioning
- Elderly get 4X less vitamin D from the same amount of sun
Elderly also spend less time outdoors and have more clothes on
- All items in category Diabetes and Vitamin D
448 items: both Type 1 and Type 2
Vitamin D appears to both prevent and treat diabetes
- Appears that >2,000 IU will Prevent
- Appears that >4,000 IU will Treat , but not cure
- Appears that Calcium and Magnesium are needed for both Prevention and Treatment
- which are just some of the vitamin D cofactors
Number of articles in both categories of Diabetes and:
- Dark Skin
22 ; Intervention 48 ; Meta-analysis 28 ; Obesity 26 ; Pregnancy 39 ; T1 (child) 34 ; Omega-3 10 ; Vitamin D Receptor 18 ; Genetics 10 ; Magnesium 18 Click here to see details 2045 visitors, last modified 03 Dec, 2014, URL: